600521 華海藥業
按盤價 
17.930 +0.380 (+2.165%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 7,247,654 | 16.76% | 8,308,720 | 8,265,745 | 6,643,573 | 6,485,213 | |
| 減：營業總成本 | 5,940,776 | 13.43% | 7,096,900 | 6,635,694 | 6,300,680 | 5,327,599 | |
| 其中:營業成本 | 2,705,991 | 6.22% | 3,288,338 | 3,110,936 | 2,657,134 | 2,352,223 | |
| 財務費用 | 121,556 | 80.08% | 137,247 | (10,833) | 188,184 | 264,872 | |
| 資產減值損失 | (34,679) | -111,978.12% | (117,176) | (70,604) | (13,928) | (32,776) | |
| 公允價值變動收益 | (51,795) | -39.00% | (100,248) | 5,201 | 299,808 | 48,481 | |
| 投資收益 | (22,389) | -59.14% | (62,652) | (75,205) | 147,151 | (22,391) | |
| 其中：對聯營企業和合營企業的投資收益 | (22,788) | 5.65% | (27,700) | (42,191) | (41,774) | (28,228) | |
| 營業利潤 | 1,316,953 | 42.48% | 1,124,540 | 1,547,171 | 868,399 | 1,286,555 | |
| 利潤總額 | 1,311,263 | 44.42% | 1,100,321 | 1,508,900 | 786,928 | 1,215,355 | |
| 減：所得稅費用 | 274,015 | 40.67% | 283,072 | 332,890 | 306,284 | 220,757 | |
| 淨利潤 | 1,037,248 | 45.44% | 817,249 | 1,176,009 | 480,644 | 994,598 | |
| 減：非控股權益 | 5,980 | -171.37% | (13,217) | 8,251 | (6,891) | 64,783 | |
| 股東淨利潤 | 1,031,268 | 42.92% | 830,466 | 1,167,759 | 487,535 | 929,815 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.710 | 42.00% | 0.570 | 0.810 | 0.340 | 0.640 | |
| 每股派息 (元) * | -- | -- | 0.200 | 0.240 | 0.100 | 0.200 | |
| 每股淨資產 (元) * | 5.831 | 10.31% | 5.286 | 4.925 | -- | 4.312 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 20/11/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
